ASIT biotech announced that all sites in its Phase III trial of gp-ASIT+™ in grass pollen rhinitis have reached the end of the grass pollen season, allowing for last patient visits according to plan, and thus confirming the study is on track to deliver results by mid-December. The Phase III trial of gp-ASIT+™, an innovative immunotherapy treatment for grass pollen allergies which is administered in only three weeks prior to the grass pollen season, has randomized 651 patients from 69 centers. A certain level of grass pollen circulation is required during the study period in order for the patients to be exposed in a real-life setting, and thus demonstrate and assess the difference with placebo. The primary objective of the study is a 0.3 absolute reduction in the Combined Symptom and Medication Score (CSMS) in the treated group compared to placebo, equaling a treatment effect of 20% between gp-ASIT+™ and placebo according to protocol hypotheses. The clinical sites were selected in collaboration with the European Aeroallergen Network (EAN) of the Medical University of Vienna, based on their pollen count history. The EAN has confirmed that all sites have reached their end of 2019 pollen season and experienced grass pollen concentration. The last visit of the protocol can now be scheduled for all patients, putting the study on track for readout, as planned, by mid-December 2019.